Cabotegravir represents an important development in long acting HIV prevention because it allows medication to be delivered through scheduled injections rather than relying only on daily oral tablets. Cabotegravir belongs to the integrase strand transfer inhibitor class of antiretroviral medicines. For HIV prevention, the injectable formulation is administered by a healthcare professional at scheduled intervals. The Centers for Disease Control and Prevention states that injectable cabotegravir is given initially, followed by another injection one month later and then every two months.
Cabotegravir works by inhibiting HIV integrase, an enzyme HIV needs to insert its genetic material into human cells. By interfering with this process, the medicine helps prevent HIV from establishing an infection when used as prescribed. Long acting cabotegravir is an option for HIV negative people who may have a substantial risk of acquiring HIV. WHO recommends CAB LA as an additional HIV prevention choice within a comprehensive prevention approach.
Key points about cabotegravir include:
Long acting HIV therapy changes how antiretroviral medicines can be delivered. Instead of depending entirely on daily tablets, certain medicines can maintain therapeutic drug levels for an extended period. This approach can be useful for people who find daily medication difficult to maintain or who prefer scheduled healthcare visits.
For cabotegravir used as PrEP, the current CDC schedule begins with an injection, followed by a second injection one month later and subsequent injections every two months. Regular appointments are important because protection depends on receiving injections according to the recommended schedule.
Important aspects of long acting cabotegravir include:
Daily oral PrEP remains an established HIV prevention option, while injectable cabotegravir provides another method for eligible people. CDC guidance states that both oral and injectable PrEP can be highly effective when taken or administered as prescribed. Injectable cabotegravir may be particularly relevant for people who have difficulty taking oral medication consistently or prefer less frequent dosing.
The choice between prevention methods can depend on medical history, potential exposure, medication interactions, preferences, access to healthcare, and the ability to attend scheduled appointments. A healthcare professional can determine which option is appropriate.
HIV testing is an important part of cabotegravir PrEP because using PrEP when someone already has an undiagnosed HIV infection can contribute to drug resistance. The FDA prescribing information specifically warns about this risk and requires HIV testing before initiation and before subsequent injections.
Some people receiving cabotegravir may experience injection site reactions. Other adverse effects can occur, and individual risks depend on health status and other medicines. Medical professionals should review a person's health history before prescribing the medication and provide appropriate follow up.
Cabotegravir is one component of comprehensive HIV prevention. Condoms can still provide protection against certain sexually transmitted infections and pregnancy, while HIV testing remains an important part of sexual health.
Modern HIV prevention continues to develop as long acting medicines become available. Cabotegravir demonstrates how antiretroviral therapy can be delivered through scheduled injections, providing an alternative to daily oral PrEP for eligible individuals. WHO recognizes long acting injectable cabotegravir as an additional HIV prevention option, while current clinical guidance emphasizes HIV testing, appropriate scheduling, medical follow up, and comprehensive prevention.